DALLAS and FORT WORTH, Texas, May 31, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that it has appointed Juergen A. Martens, PhD, to the position of Chief Technology and Operations Officer.
Dr. Martens most recently served as Chief Operating Officer of MannKind Corporation from January 2015 to March 2016, and as the company’s Corporate Vice President of Operations and Chief Technology Officer from 2005 to 2015. From 2000 to 2005 he was Vice President of Pharmaceutical Technology Development at Nektar Therapeutics. Previously, he held technical management positions at Aerojet Fine Chemicals and FMC Corporation. Dr. Martens also held a variety of management positions with increased managerial responsibility in R&D, plant management, and business process development at Lonza, in Switzerland and in the United States.
“Juergen’s depth and breadth of experience in drug delivery technologies and manufacturing operations will be invaluable resources for Neos as we launch Adzenys XR-ODT™ and advance our promising pipeline of product candidates, including Cotempla XR-ODT and NT-0201, toward the market,” said Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics. “I am very pleased to welcome him to the Neos team.”
Dr. Martens holds a bachelor’s degree in chemical engineering from the Technical College Mannheim/Germany, a bachelor’s and master’s degree in Chemistry and a doctorate in Physical Chemistry from the University of Marburg/Germany. Dr. Martens obtained an executive master’s degree in Management (EMTM) from the University of Pennsylvania, a joint program of the Wharton School of Business & the School of Engineering and Applied Science.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platforms. Adzenys XR-ODT™ is the first and only commercially available amphetamine extended-release orally disintegrating tablet for the treatment of ADHD. Neos has two other branded product candidates in development, an XR-ODT of methylphenidate and a liquid suspension of amphetamine for the treatment of ADHD. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®1, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
